Get started
Author

Ségolène Bisot-Locard

Observed names: Bisot-Locard, Ségolène, S Bisot-Locard, S. Bisot-LOcard, S. Bisot-Locard, Segolene Bisot-Locard, Segolène Bisot-Locard, Ségolene Bisot-Locard
Observed institutions: Inserm, Novartis (France), Netris Pharma (France), Hôpital Lyon Sud, Hôpital Edouard Herriot, Institut Bergonié, Centre Hospitalier Universitaire de Saint-Pierre
ORCID: 0000-0001-5619-9758
Observed ORCID: 0000-0001-5619-9758
OpenAlex ID: A5032836718
Octreotide (Long-Acting Release Formulation) Treatment in Patients with Graves’ Orbitopathy: Clinical Results of a Four-Month, Randomized, Placebo-Controlled, Double-Blind Study
2005 · J. L. Wémeau, P. Caron, et al. · The Journal of Clinical Endocrinology & Metabolism · 83
PDF
The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists
2010 · Geneviève Monges, Ségolène Bisot-Locard, et al. · Bulletin du Cancer · 66
Management of hyperglycaemia in Cushing's disease: Experts’ proposals on the use of pasireotide
2012 · Y. Reznik, J. Bertherat, et al. · Diabetes & Metabolism · 60
Predictive Factors of Somatostatin Receptor Ligand Response in Acromegaly—A Prospective Study
2022 · Mirela-Diana Ilie, Antoine Tabarin, et al. · The Journal of Clinical Endocrinology & Metabolism · 53
PDF
Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey among French Pathologists (the PRONET Study)
2016 · Jean-Yves Scoazec, Anne Couvelard, et al. · Neuroendocrinology · 50
SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction
2012 · Guillemette Laval, Hubert Rousselot, et al. · Bulletin du Cancer · 44
Patients lost to follow-up in acromegaly: results of the ACROSPECT study
2014 · B Delemer, Ph Chanson, et al. · European Journal of Endocrinology · 22
Socio-psychological impact of infused iron chelation therapy with deferoxamine in metropolitan France: ISOSFER study results
2009 · Isabelle Thuret, Maya Hacini, et al. · Hematology · 21
PDF
Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis
2010 · Patrice Fardellone, Bernard Cortet, et al. · Joint Bone Spine · 20
Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration
2008 · S. Y. Cohen, D. Bremond-Gignac, et al. · Graefe s Archive for Clinical and Experimental Ophthalmology · 17
EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib
2018 · Olivier Bouché, Axel Le Cesne, et al. · PLoS ONE · 12
PDF
Incidence of gastrointestinal stromal tumors (GISTs) in France: Results of the PROGIST survey conducted among pathologists
2007 · G. Monges, J. Coindre, et al. · Journal of Clinical Oncology · 10
Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study
2022 · Denis Smith, Côme Lepage, et al. · Advances in Therapy · 9
PDF
Low prevalence of antibodies to hepatitis C virus in patients with Hashimoto's thyroiditis
1995 · Ségolène Bisot-Locard, Hubert Bornet, et al. · Journal of Hepatology · 4
La valeur ajoutée relative : quels outils pour l’évaluer ?
2008 · Claire Le Jeunne, Marie-Christine Woronoff-Lemsi, et al. · Therapies · 3
Evaluation of Nurses’ and Patients’ Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR®): A French Observational Study
2020 · Brigitte Delemer, Thierry Nguyen-Tan-Hon, et al. · Advances in Therapy · 2
Modélisation coût-efficacité de l’administration annuelle d’acide zolédronique versus les stratégies usuelles de traitement de l’ostéoporose post-ménopausique
2010 · Patrice Fardellone, Bernard Cortet, et al. · Revue du Rhumatisme · 1
Pin53 Pharmacy-implemented Guidelines on Switching From Intravenousto Oral Antibiotics: a Prospective Study in a Teaching Hospital
2008 · C Briquet, W D'Hoore, et al. · Value in Health · 1
PDF
Relative Added Value: What are the Tools to Evalue it?
2008 · Claire Le Jeunne, Marie-Christine Woronoff-Lemsi, et al. · Therapies · 1
966P IMMUNONET: A proof of concept phase II evaluating NP137 as add on therapy in solid tumors under standard immunotherapies: Interim analysis of primary and secondary refractory cohorts
2025 · J. Fayette, E.B. Saada, et al. · Annals of Oncology
Predictive factors of somatostatin receptor ligand response in acromegaly - a prospective study
2022 · Ilie Mirela Diana, Antoine Tabarin, et al. · Endocrine Abstracts
Prise en charge des angiomyolipomes rénaux multiples (AML) chez les patients atteints de sclérose tubéreuse de Bourneville (STB) - résultats de l’étude observationnelle OSCAR
2018 · D. Joly, E. Kalbacher, et al. · Néphrologie & Thérapeutique
Hyperglycémie induite par l’analogue de somatostatine pasiréotide au cours de la maladie de Cushing
2015 · Y. Reznik, S. Bisot-Locard, et al. · Médecine des Maladies Métaboliques
Pasiréotide LP versus octréotide LP chez les patients acromégales : résultats d’une étude de phase III, multicentrique, randomisée, en double-aveugle
2012 · A. Tabarin, T. Brue, et al. · Annales d Endocrinologie
Évérolimus dans le traitement des angiomyolipomes des reins associés à une sclérose tubéreuse de Bourneville ou à une lymphangioléïomyomatose sporadique : résultats initiaux de l’étude EXIST-2
2012 · D. Chauveau, S. Bisot-Locard, et al. · Néphrologie & Thérapeutique
Works count: 33
Citation count: 479
H-index: 11
I10-index: 12
Year
Topic
Type